Sirona Biochem Corp Stock Performance
| SRBCF Stock | USD 0.04 0 7.74% |
The entity has a beta of 0.89, which indicates possible diversification benefits within a given portfolio. Sirona Biochem returns are very sensitive to returns on the market. As the market goes up or down, Sirona Biochem is expected to follow. At this point, Sirona Biochem Corp has a negative expected return of -0.27%. Please make sure to validate Sirona Biochem's skewness, as well as the relationship between the rate of daily change and price action indicator , to decide if Sirona Biochem Corp performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Sirona Biochem Corp has generated negative risk-adjusted returns adding no value to investors with long positions. Despite fragile performance in the last few months, the Stock's fundamental indicators remain nearly stable which may send shares a bit higher in April 2025. The current disturbance may also be a sign of long-run up-swing for the company stockholders. ...more
| Begin Period Cash Flow | 1.5 M |
Sirona |
Sirona Biochem Relative Risk vs. Return Landscape
If you would invest 5.20 in Sirona Biochem Corp on December 5, 2024 and sell it today you would lose (1.03) from holding Sirona Biochem Corp or give up 19.81% of portfolio value over 90 days. Sirona Biochem Corp is currently producing negative expected returns and takes up 4.5526% volatility of returns over 90 trading days. Put another way, 40% of traded pink sheets are less volatile than Sirona, and 99% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
Sirona Biochem Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Sirona Biochem's investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as Sirona Biochem Corp, and traders can use it to determine the average amount a Sirona Biochem's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.059
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | SRBCF |
Estimated Market Risk
| 4.55 actual daily | 40 60% of assets are more volatile |
Expected Return
| -0.27 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.06 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Sirona Biochem is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Sirona Biochem by adding Sirona Biochem to a well-diversified portfolio.
Sirona Biochem Fundamentals Growth
Sirona Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Sirona Biochem, and Sirona Biochem fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Sirona Pink Sheet performance.
| Return On Equity | -35.56 | |||
| Return On Asset | -1.35 | |||
| Operating Margin | (4.92) % | |||
| Current Valuation | 24.5 M | |||
| Shares Outstanding | 251.73 M | |||
| Price To Earning | (7.33) X | |||
| Price To Book | 36.93 X | |||
| Price To Sales | 36.46 X | |||
| Revenue | 268.02 K | |||
| EBITDA | (2.3 M) | |||
| Cash And Equivalents | 1.13 M | |||
| Total Debt | 468.77 K | |||
| Debt To Equity | 0.60 % | |||
| Book Value Per Share | 0 X | |||
| Cash Flow From Operations | (2.16 M) | |||
| Earnings Per Share | (0.01) X | |||
| Total Asset | 1.29 M | |||
| Retained Earnings | (12.03 M) | |||
| Current Asset | 1.49 M | |||
| Current Liabilities | 801 K | |||
About Sirona Biochem Performance
By analyzing Sirona Biochem's fundamental ratios, stakeholders can gain valuable insights into Sirona Biochem's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Sirona Biochem has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Sirona Biochem has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Sirona Biochem Corp., a cosmetic ingredient and drug discovery company, develops and sells cosmetic and pharmaceutical active ingredients in Canada and France. The company was incorporated in 2006 and is headquartered in Vancouver, Canada. Sirona Biochem is traded on OTC Exchange in the United States.Things to note about Sirona Biochem Corp performance evaluation
Checking the ongoing alerts about Sirona Biochem for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Sirona Biochem Corp help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Sirona Biochem Corp generated a negative expected return over the last 90 days | |
| Sirona Biochem Corp has some characteristics of a very speculative penny stock | |
| Sirona Biochem Corp has high historical volatility and very poor performance | |
| The company reported the revenue of 268.02 K. Net Loss for the year was (2.31 M) with profit before overhead, payroll, taxes, and interest of 199.25 K. | |
| Sirona Biochem Corp has accumulated about 1.13 M in cash with (2.16 M) of positive cash flow from operations. |
- Analyzing Sirona Biochem's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Sirona Biochem's stock is overvalued or undervalued compared to its peers.
- Examining Sirona Biochem's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Sirona Biochem's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Sirona Biochem's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Sirona Biochem's pink sheet. These opinions can provide insight into Sirona Biochem's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Sirona Pink Sheet analysis
When running Sirona Biochem's price analysis, check to measure Sirona Biochem's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sirona Biochem is operating at the current time. Most of Sirona Biochem's value examination focuses on studying past and present price action to predict the probability of Sirona Biochem's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sirona Biochem's price. Additionally, you may evaluate how the addition of Sirona Biochem to your portfolios can decrease your overall portfolio volatility.
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation |